Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Clinical Trial ID NCT03127111

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03127111

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.	N Engl J Med	2016	8.53
2	Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.	Gastroenterology	2004	4.03
3	Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.	Nat Genet	2015	2.76
4	Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.	Proc Natl Acad Sci U S A	2010	2.43
5	Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.	J Natl Cancer Inst	2007	2.11
6	5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.	Gastroenterology	2010	1.71
7	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.	Int J Cancer	2013	1.60
8	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2014	1.57
9	Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.	Ann Surg	2014	1.46
10	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.	J Clin Oncol	2013	1.41
11	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes.	Carcinogenesis	2012	1.16
12	GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis.	Eur J Cancer	2011	1.13
13	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clin Cancer Res	2014	1.08
14	Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.	Clin Cancer Res	2012	1.08
15	Identification of novel germline polymorphisms governing capecitabine sensitivity.	Cancer	2012	0.89
16	SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.	Int J Cancer	2016	0.77
17	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.	Nat Rev Cancer	2017	0.75